在欧洲资助多国研究者发起的临床研究:为何与如何
本文阐述研究者发起的临床研究(IICS)聚焦产业界常忽视但具高社会价值的问题,多国IICS通过交流研究思路与技术提升数据科学质量,且不同地域、社会与民族背景患者的参与使结果更具通用性;但公共资助的多国IICS面临预算与费用资格期限受限、资金难以跨国调动、招标规则及费用报告复杂等障碍,文中描述了支持多国IICS的必要性、目标及欧洲现行资助机制。
要点
- IICS研究问题包括已上市治疗的新适应证(药物再利用)、健康产品/治疗方案比较优化及先进疗法创新。
- 多国IICS由非营利/学术机构申办并公共资助,但公共资助是开展IICS尤其是IICT的主要挑战。
- 公共资助多国IICT的主要障碍包括预算与费用资格期限受限、资金跨国调动缺乏灵活性、招标规则及费用报告复杂。
核心结论
- 多国IICS的资助策略应演进以缓解已识别的障碍,从而促进那些制药与医疗器械产业资助的研究不太可能回答的高度相关医疗问题的研究。
研究设计与样本
- 本文为论述性文章,描述支持多国IICS的必要性、其目标及欧洲现行资助机制。
主要发现
- 产业界可能将重点与资源投向最终能为公司带来收入的结果与产品的研究。
- IICS研究问题包括(a)改进或获得可用治疗的新适应证(药物再利用);(b)通过比较各种健康产品或治疗方案进行优化;(c)创新,尤其是先进疗法。
- 多国IICS通过交流研究思路、科学技术与工具提高数据科学质量。
- 来自不同地理、社会与民族背景患者的参与增加研究结果的价值,并产生比局限于单一地理位置的研究更具通用性的证据。
- 多国IICS通常由非营利/学术机构申办并公共资助。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Investigator-initiated clinical studies (IICSs), also referred to as non-commercial, academic or independent clinical studies, address important research questions that are usually neglected by industry despite their high societal value. Indeed, industry may direct their focus and resources on studies that will yield results and products that can ultimately generate revenue for the company. Conversely, IICS research questions include (a) refining or getting new indications of available treatments (drug repurposing); (b) optimisation, by comparing various health products or treatment regimens; and (c) innovation, especially for advanced therapies. Multinational IICSs increase the scientific quality of the data by exchange of research ideas, scientific techniques and tools. Participation of patients from different geographical, social and ethnic backgrounds equally adds to the value of study results and yields more generalisable evidence than a study confined to a single geographical location. Multinational IICSs are generally sponsored by non-profit/academic organisations and publicly funded. Funding has been already identified as a main challenge for the conduct IICS and especially for clinical trials (IICTs, IICS where a medical intervention is directly tested). Main barriers to the conduct of multinational IICTs with public funding include: Limitations of budget and duration of the eligibility of costs Lack of flexibility to move funds transnationally Tendering rules Complexity in the reporting of the eligible costs to funders We describe why there is a need to support multinational IICS, what should be their objectives and what are the current funding mechanisms in Europe. Strategies for funding multinational IICS should evolve to mitigate identified barriers, thus facilitating research that can provide answers to highly relevant questions in healthcare which are less likely to be answered by studies funded by the pharmaceutical and medical device industry.
引用
- Del Álamo M, Lémeret S, Nieto C, et al. Funding multinational investigator-initiated clinical studies in Europe: why and how? Trials. 2024. PMID: 39420404. doi:10.1186/s13063-024-08548-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。